Table 1 CardioBoost outperforms existing genome-wide tools for the classification of holdout test variants.
% | Cardiomyopathies | Arrhythmias | ||||
|---|---|---|---|---|---|---|
CardioBoost | M-CAP | REVEL | CardioBoost | M-CAP | REVEL | |
Overall accuracy | 63.3a | 28.4 | 17.4 | 81.2a | 30.5 | 37 |
Proportion of variants classified with high confidence | 70.2a | 33.9 | 22 | 88.3a | 33.8 | 40.3 |
Accuracy of high-confidence classifications | 90.2 | 83.8 | 79.2 | 91.9 | 90.4 | 91.9 |
Proportion of variants with indeterminate classification | 29.8a | 66.1 | 78 | 11.7a | 66.2 | 59.7 |
TPR | 69.5a | 41.5 | 28 | 83.3a | 48.8 | 65.5 |
PPV | 86.3 | 81.7 | 76.7 | 90.9 | 91.1 | 91.7 |
TNR | 56a | 13 | 5 | 78.6a | 8.6 | 2.9 |
NPV | 96.6 | 92.9 | 100 | 93.2 | 85.7 | 100 |